MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

MET inhibitor tepotinib antagonizes multidrug resistance mediated by ABCG2 transporter: In vitro and in vivo study

Overexpression of ABCG2 transporter in cancer cells has been linked to the development of multidrug resistance (MDR), an obstacle to cancer therapy. Our recent study uncovered that the MET inhibitor, tepotinib, is a potent reversal agent for ABCB1-mediated MDR. In the present study, we reported for...

Full description

Bibliographic Details
Main Authors:	Zhuo-Xun Wu, Qiu-Xu Teng, Yuqi Yang, Nikita Acharekar, Jing-Quan Wang, Min He, Sabesan Yoganathan, Jun Lin, Jian Wang, Zhe-Sheng Chen
Format:	Article
Language:	English
Published:	Elsevier 2022-05-01
Series:	Acta Pharmaceutica Sinica B
Subjects:	MET inhibitor Tepotinib Multidrug resistance ABCG2 transporter Reversal agent Combination treatment
Online Access:	http://www.sciencedirect.com/science/article/pii/S2211383521004901

Similar Items

Responses to the Tepotinib in Gastric Cancers with MET Amplification or MET Exon 14 Skipping Mutations and High Expression of Both PD-L1 and CD44
by: Sung-Hwa Sohn, et al.
Published: (2022-07-01)

Dramatic intracranial response to tepotinib in a patient with lung adenocarcinoma harboring MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2021-03-01)

Successful and Prompt Treatment with Tepotinib for Lung Adenocarcinoma Harboring MET Exon 14 Skipping Mutation Combined with Lung Abscess Formation: A Case Report
by: Go Makimoto, et al.
Published: (2022-05-01)

Capmatinib successfully overcomes tepotinib‐induced intolerable peripheral edema
by: Kei Kunimasa, et al.
Published: (2021-12-01)

Comparison of Tepotinib, Paclitaxel, or Ramucirumab Efficacy According to the Copy Number or Phosphorylation Status of the <i>MET</i> Gene: Doublet Treatment versus Single Agent Treatment
by: Sung-Hwa Sohn, et al.
Published: (2024-02-01)

Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
by: Brazel D, et al.
Published: (2022-05-01)

First-line tepotinib for a very elderly patient with metastatic NSCLC harboring MET exon 14 skipping mutation and high PD-L1 expression
by: Alessandro Inno, et al.
Published: (2023-10-01)

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation–Positive Lung Adenocarcinoma: Case Report
by: Taira Ninomaru, MD, et al.
Published: (2021-03-01)

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report
by: Liang-Wei Tseng, et al.
Published: (2022-10-01)

Poziotinib Inhibits the Efflux Activity of the ABCB1 and ABCG2 Transporters and the Expression of the ABCG2 Transporter Protein in Multidrug Resistant Colon Cancer Cells
by: Yongchao Zhang, et al.
Published: (2020-11-01)

A case of successful desensitization treatment with tepotinib after tepotinib-induced rash
by: Tomoki Tamura, et al.
Published: (2023-01-01)

Design, Synthesis, and Evaluation of New Mesenchymal–Epithelial Transition Factor (c-Met) Kinase Inhibitors with Dual Chiral Centers
by: Han Yao, et al.
Published: (2022-08-01)

Imperatorin Restores Chemosensitivity of Multidrug-Resistant Cancer Cells by Antagonizing ABCG2-Mediated Drug Transport
by: Chung-Pu Wu, et al.
Published: (2023-11-01)

AZ32 Reverses ABCG2-Mediated Multidrug Resistance in Colorectal Cancer
by: Kun Liu, et al.
Published: (2021-05-01)

Tivantinib, A c-Met Inhibitor in Clinical Trials, Is Susceptible to ABCG2-Mediated Drug Resistance
by: Zhuo-Xun Wu, et al.
Published: (2020-01-01)

Case report: Success of tepotinib therapy in overcoming resistance to osimertinib in a patient with EGFR-mutant lung adenocarcinoma with a potential acquired MET exon 14 skipping mutation
by: Shinkichi Takamori, et al.
Published: (2022-10-01)

Posttranscriptional Regulation of the Human ABCG2 Multidrug Transporter Protein by Artificial Mirtrons
by: Anita Schamberger, et al.
Published: (2021-07-01)

M3814, a DNA-PK Inhibitor, Modulates ABCG2-Mediated Multidrug Resistance in Lung Cancer Cells
by: Zhuo-Xun Wu, et al.
Published: (2020-05-01)

GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs
by: Ze-Zhong Yu, et al.
Published: (2023-11-01)

A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo
by: Shoji Kokubo, et al.
Published: (2021-11-01)

BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance
by: Yunali V. Ashar, et al.
Published: (2020-09-01)

Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor
by: Zhuo-Xun Wu, et al.
Published: (2021-07-01)

Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo
by: Dimitrios Vagiannis, et al.
Published: (2021-11-01)

Hydroxygenkwanin Improves the Efficacy of Cytotoxic Drugs in ABCG2-Overexpressing Multidrug-Resistant Cancer Cells
by: Yan-Qing Li, et al.
Published: (2022-10-01)

Expression, Function and Trafficking of the Human ABCG2 Multidrug Transporter Containing Mutations in an Unstructured Cytoplasmic Loop
by: Orsolya Mózner, et al.
Published: (2023-10-01)

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non‐small cell lung cancer: A case report
by: Satoshi Ikeo, et al.
Published: (2023-04-01)

VS-4718 Antagonizes Multidrug Resistance in ABCB1- and ABCG2-Overexpressing Cancer Cells by Inhibiting the Efflux Function of ABC Transporters
by: Ning Ji, et al.
Published: (2018-10-01)

Cellular Processing of the ABCG2 Transporter—Potential Effects on Gout and Drug Metabolism
by: Orsolya Mózner, et al.
Published: (2019-10-01)

Ellagic Acid and Schisandrins: Natural Biaryl Polyphenols with Therapeutic Potential to Overcome Multidrug Resistance in Cancer
by: Sabesan Yoganathan, et al.
Published: (2021-02-01)

Reversal of Cancer Multidrug Resistance (MDR) Mediated by ATP-Binding Cassette Transporter G2 (ABCG2) by AZ-628, a RAF Kinase Inhibitor
by: Jing-Quan Wang, et al.
Published: (2020-12-01)

The multi-targeted tyrosine kinase inhibitor SKLB610 resensitizes ABCG2-overexpressing multidrug-resistant cancer cells to chemotherapeutic drugs
by: Chung-Pu Wu, et al.
Published: (2022-05-01)

Snapshots of ABCG1 and ABCG5/G8: A Sterol’s Journey to Cross the Cellular Membranes
by: Fatemeh Rezaei, et al.
Published: (2022-12-01)

Effects of High-Intensity Resistance Training and Aerobic Exercise on Expression of ABCG4, ABCG5 and ABCG8 Genes in Female Athletes
by: Reza Bagheri, et al.
Published: (2020-05-01)

Erdafitinib Antagonizes ABCB1-Mediated Multidrug Resistance in Cancer Cells
by: Weiguo Feng, et al.
Published: (2020-06-01)

The Novel Benzamide Derivative, VKNG-2, Restores the Efficacy of Chemotherapeutic Drugs in Colon Cancer Cell Lines by Inhibiting the ABCG2 Transporter
by: Silpa Narayanan, et al.
Published: (2021-02-01)

An LC–MS/MS Analytical Method for Quantifying Tepotinib in Human Liver Microsomes: Application to In Vitro and In Silico Metabolic Stability Estimation
by: Mohamed W. Attwa, et al.
Published: (2023-05-01)

Beneficial effect of ezetimibe-atorvastatin combination therapy in patients with a mutation in ABCG5 or ABCG8 gene
by: Hayato Tada, et al.
Published: (2020-01-01)

Reversal Effect of ALK Inhibitor NVP-TAE684 on ABCG2-Overexpressing Cancer Cells
by: Jingqiu Wang, et al.
Published: (2020-02-01)

ABCG5 and ABCG8 gene variations associated with sitosterolemia and platelet dysfunction
by: Jose María Bastida, et al.
Published: (2021-05-01)

ABCG2 in Acute Myeloid Leukemia: Old and New Perspectives
by: Daniela Damiani, et al.
Published: (2023-04-01)